anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The link between chronic inflammation and cancer development is well acknowledged. Inflammatory bowel disease including ulcerative colitis and Crohn's disease frequently promotes colon cancer development. Thus, control of intestinal inflammation is a therapeutic strategy to prevent and manage colitis-associated colorectal cancer (CRC). Recently, gut mucosal damage-associated molecular patterns S100A8 and S100A9, acting via interactions with their pattern recognition receptors (PRRs), especially TLR4 and RAGE, have emerged as key players in the pathogenesis of colonic inflammation. We found elevated serum levels of S100A8 and S100A9 in both colitis and colitis-associated CRC mouse models along with significant increases in their binding with PRR, TLR4, and RAGE. In this study we developed a dual PRR-inhibiting peptide system (rCT-S100A8/A9) that consisted of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9, and conjugated with a CT peptide (TWYKIAFQRNRK) for colon-specific delivery. In human monocyte THP-1 and mouse BMDMs, S100A8/A9-derived peptide comprising TLR4- and RAGE-interacting motif (0.01, 0.1, 1 μM) dose-dependently inhibited the binding of S100 to TLR4 or RAGE, and effectively inhibited NLRP3 inflammasome activation. We demonstrated that rCT-S100A8/A9 had appropriate drug-like properties including in vitro stabilities and PK properties as well as pharmacological activities. In mouse models of DSS-induced acute and chronic colitis, injection of rCT-S100A8/A9 (50 μg·kg-1·d-1, i.p. for certain consecutive days) significantly increased the survival rates and alleviated the pathological injuries of the colon. In AOM/DSS-induced colitis-associated colorectal cancer (CAC) mouse model, injection of rCT-S100A8/A9 (50 μg·kg-1·d-1, i.p.) increased the body weight, decreased tumor burden in the distal colon, and significantly alleviated histological colonic damage. In mice bearing oxaliplatin-resistant CRC xenografts, injection of rCT-S100A8/A9 (20 μg/kg, i.p., every 3 days for 24-30 days) significantly inhibited the tumor growth with reduced EMT-associated markers in tumor tissues. Our results demonstrate that targeting the S100-PRR axis improves colonic inflammation and thus highlight this axis as a potential therapeutic target for colitis and CRC.
PURPOSE: A cosmetic composition containing Xanthium strumarium extract for suppressing sebum secretion is provided to prevent excessive sebum secretion and to treat sebum secretion-associated diseases. CONSTITUTION: A cosmetic composition for suppressing sebum secretion contains Xanthium strumarium extract. The Xanthium strumarium extract is used for treat acne, alopecia, or dermatitis seborrheica. The Xanthium strumarium extract is contained in 0.0001-30 weight% based on total weight. The Xanthium strumarium extract is obtained using water, low alcohol of 1-4 carbon atoms, acetone, ethyl acetate, butyl acetate, or 1,3-butylene glycol. The cosmetic composition is manufactured in the form of solution, suspension, emulsion, paste, gel, cream, lotion, surfactant-containing cleansing, oil, powder foundation, wax foundation, or spray.
Chronic Granulomatous Disease (CGD) is an inherited disorder of neutrophil function. Patients are profoundly immunocompromised and are plagued early in life with recurrent and life threatening infections. The prognosis for CGD patients whose infection persists despite appropriate medical and surgical intervention is extremely poor. Allogeneic stem cell transplantation can cure CGD however the mortality of this procedure is high for patients who are actively infected. Ongoing clinical trials at the NIH and elsewhere suggest that the use of non-myeloablative conditioning for allogeneic stem cell transplantation is safer and less toxic for patients who are free of infection at the time of transplant. The goal of this phase II study is to investigate the safety and efficacy of this novel approach to allogeneic stem cell transplantation for CGD patients who are actively infected. Following a preparative regimen designed to provide intense immunosuppression without myeloablation, patients will receive a peripheral blood stem cell graft from an HLA identical parent or sibling. Donor T-cells will be infused post-transplant if donor stem engraftment is unsatisfactory.

The end points of this study are engraftment, degree of donor-host chimerism, incidence of acute and chronic GvHD, infection status, immune reconstitution, and transplant related morbidity and mortality.
Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
FIELD: biotechnology, food and medicinal industry. SUBSTANCE: invention proposes the consortium of bifidobacteria and lactobacilli Bifidobacterium bifidum 1, B. bifidum 791, B. breve 79-119, B. breve 79-88, B. infantis 73-15, B. infantis 79-43, Lactobacillus plantarum 8-RA-3, L. fermentum 90-TS-4, GKNM MNIIEM named for G.N. Gabritchevsky, N 159 used for preparing bacterial preparations, ferments for fermented-milk foodstuffs, fermented and nonfermented foodstuffs, biologically active supplements designated for correction of microflora in children in age below 3 years. The consortium is designated for correction of intestine microflora, mucous, opened cavities, cutaneous integuments in children of age below 3 years. The strain shows immunocorrecting action and provides the enhanced protective, immunotrophic, metabolic and digestive functions because of synergetic effect of bifidobacteria and lactobacilli as components of its composition that stimulates the growth of normal microflora. EFFECT: expanded arsenal of technical agents of curative-prophylaxis designation. 3 tbl, 5 ex
The invention discloses a polypeptide with histone methylase DOT1L dimethylation inhibition activity, an inhibitor, a design method and application thereof, wherein the amino acid sequence of the polypeptide is shown as Seq No. 1. The inhibitor comprises the polypeptide. The design method comprises the following steps: s1, obtaining the crystal structure of the AF10-DOT1L compound, and finding out a polypeptide precursor capable of inhibiting the combination of DOT 1L; s2, obtaining an AF 10-polypeptide precursor compound crystal; s3, designing a polypeptide fragment specifically binding to AF 10; s4, further optimizing the polypeptide with the activity of inhibiting the methylation of histone methylase DOT1L on the basis of S3. The invention also comprises the application of the polypeptide in the preparation of medicines for inhibiting the histone demethylase DOT 1L. Compared with the prior art, the polypeptide has the function of specifically inhibiting the dimethylation activity of histone methylase DOT1L, and has good application prospect.
PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1 cardio-selectivity, however, metoprolol succinate extended-release may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol succinate extended-release. Bronchodilators, including beta2-agonists, should be readily available or administered concomitantly [see Error! Hyperlink reference not valid.].
The present disclosure is directed to methods and apparatus for centralized de-identification of protected data associated with subjects. In various embodiments, de-identified data may be received (1102) that includes de-identified data set(s) associated with subject(s) that is generated from raw data set(s) associated with the subjects. Each of the raw data set(s) may include identifying feature(s) that are usable to identify the respective subject. At least some of the identifying feature(s) may be absent from or obfuscated in the de-identified data. Labels associated with each of the de-identified data sets may be determined (1104). At least some of the de-identified data sets may be applied (1108) as input across a trained machine learning model to generate respective outputs, which may be compared (1110) to the labels to determine a measure of vulnerability of the de-identified data to re-identification.
INTRODUCTION: The choice between hemiarthroplasty (HA) and total hip arthroplasty (THA) for displaced femoral neck fractures remains debated. There is increasing use in dual mobility cup total hip arthroplasty (DMC-THA) to prevent dislocations in these high-risk patients. Aim of this study is to retrospectively analyze patients treated in a single Center for femoral neck fracture comparing HA and DMC-THA in terms of: functional outcome, rate of complications and mortality.
MATERIAL AND METHODS: Between 2020 and 2022, 162 patients were included, 39 male and 123 female, with a mean age of 76 years old. HA were implanted in 82 cases and DMC-THA in 80 cases. INCLUSION CRITERIA WERE: age < 85 years old, American Society of Anesthesiologists (ASA) score below 3, minimum follow-up of 6 months. Overall, 124/162 of patients (77%) were surgically treated within 48 h from admission.
RESULTS: The mean age for DMC-THA group was 74 years old and 78 years old for HA group. The overall mean surgical time was significantly higher in the DMC-THA group (P < 0.001). Mean hemoglobin (Hb) loss was 1.64 g/dl in the HA group and 1.72 g/dl in the DMC-THA group with no differences between the two groups (P = 0.573). There is no difference in survival of patients between the two groups (P = 0.7704). In the HA group, the mean one-month post-operative VAS score was 2.1, while in the DMC-THA group was 0.9. The Harris hip score was significantly better in DMC-THA group (P = 0.035) Dislocation never occured in the overall series. Infection occurred only in one patient with DMC-THA and was treated with debridement. Periprosthetic fracture occurred in 2 cases of DMC-THA both within 1 month from the first surgery; one was treated with revision femoral stem and the second one with fixation.
CONCLUSIONS: DMC-THA offer better functional results than HA in elderly patients with femur neck fractures. The mean surgical time was longer in DMC-THA but this did not influence blood loss, time of discharge or one-year mortality. In our series dislocation never occurred in both groups.
Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
Store at temperatures between 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59 to 86) [see USP Controlled Room Temperature].

EOVIST is a ready-to-use solution for single use only. Visually inspect EOVIST for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or if particulate matter is present. The rubber stopper should not be pierced more than once. Use EOVIST immediately after opening. Unused portions should be discarded.
To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
A compound, solution of carrier and the compound and a medical procedure is provided for suction lipolysis. The compound is preferably either one or more enzymes and/or emulsifying agents and/or detergents which digest or dissolve fat in the subcutaneous tissues. Both enzymes which degrade fats and emulsifying agents can be used according to the invention. The carrier is preferably a saline solution. A suction lipolysis procedure is provided including the steps of providing a biological and/or chemical compound which digests or dissolves fat in the subcutaneous tissues. The compound is dissolved into a saline solution and/or is suspended in a saline solution. The combination compound and saline solution is then heated to the body temperature (temperature of the patient or subject). The compound and saline solution including the compound is then injected into the subcutaneous tissue. Liposuction is then performed (suction lipectomy). The step of performing liposuction is preferably initiated after a period of time has elapsed after the saline solution and compound are infiltrated into the subcutaneous tissue.
No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
Globally, traumatic injury is a leading cause of suffering and death. The ability to curtail damage and ensure survival after major injury requires a time-sensitive response balancing organ perfusion, blood loss, and portability, underscoring the need for novel therapies for the prehospital environment. Currently, there are few options available for damage control resuscitation (DCR) of trauma victims. We hypothesize that synthetic polymers, which are tunable, portable, and stable under austere conditions, can be developed as effective injectable therapies for trauma medicine. In this work, we design injectable polymers for use as low volume resuscitants (LVRs). Using RAFT polymerization, we evaluate the effect of polymer size, architecture, and chemical composition upon both blood coagulation and resuscitation in a rat hemorrhagic shock model. Our therapy is evaluated against a clinically used colloid resuscitant, Hextend. We demonstrate that a radiant star poly(glycerol monomethacrylate) polymer did not interfere with coagulation while successfully correcting metabolic deficit and resuscitating animals from hemorrhagic shock to the desired mean arterial pressure range for DCR - correcting a 60 % total blood volume (TBV) loss when given at only 10 % TBV. This highly portable and non-coagulopathic resuscitant has profound potential for application in trauma medicine.
ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for \~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.
A human body diagram anesthesia recording system comprises a human body diagram module, a medicament database, a pipeline database and an input interface. The body map module comprises a body map and a plurality of part labels. The medicament database stores a plurality of medicament information. The pipeline database stores a plurality of pipeline information. The input interface is suitable for selecting the part volume label, the medicament information and the pipeline information on the human body diagram and establishing the association between the selected part volume label, the medicament information and the pipeline information. The invention has the beneficial effects.
Moyamoya disease (MMD) is a cerebrovascular disorder marked by progressive arterial narrowing, categorized into six stages known as Suzuki stages based on angiographic features. Growing evidence indicates a pivotal role of systemic immune and inflammatory responses in the initiation and advancement of MMD. This study employs high-dimensional mass cytometry to reveal the immunophenotypic characteristics of peripheral blood immune cells (PBMCs) at various Suzuki stages, offering insights into the progression of MMD. PBMC samples from eight patients with early-stage MMD (Suzuki stages II and III) and eight patients with later-stage MMD (Suzuki stages IV, V, and VI) were analyzed using high-dimensional mass cytometry to evaluate the frequency and phenotype of immune cell subtypes. We identified 15 cell clusters and found that the immunological features of early-stage MMD and later-stage MMD are composed of cluster variations. In this study, we confirmed that, compared to later-stage MMD, the early-stage MMD group exhibits an increase in non-classical monocytes. As the Suzuki stage level increases, the proportions of plasmacytoid DCs and monocyte-derived DCs decrease. Furthermore, T cells, monocytes, DCs, and PMN-MDSCs in the early-stage MMD group show activation of the canonical NF-κB signaling pathway. We summarized and compared the similarities and differences between early-stage MMD patients and later-stage MMD patients. There is a potential role of circulating immune dysfunction and inflammatory responses in the onset and development of MMD.
In this in vitro study, for the first time, we evaluate the effects of simvastatin-loaded liposome nanoparticles (SIM-LipoNPs) treatment on fibrosis-induced liver microtissues, as simvastatin (SIM) has shown potential benefits in the non-alcoholic fatty liver disease process. We developed multicellular liver microtissues composed of hepatic stellate cells, hepatoblastoma cells and human umbilical vein endothelial cells. The microtissues were supplemented with a combination of palmitic acid and oleic acid to develop fibrosis models. Subsequently, various groups of microtissues were exposed to SIM and SIM-LipoNPs at doses of 5 and 10 mg/mL. The effectiveness of the treatments was evaluated by analysing cell viability, production of reactive oxygen species (ROS) and nitric oxide (NO), the expression of Kruppel-like factor (KLF) 2, and pro-inflammatory cytokines (interleukin(IL)-1 α, IL-1 β, IL-6 and tumour necrosis factor-α), and the expression of collagen I. Our results indicated that SIM-LipoNPs application showed promising results. SIM-LipoNPs effectively amplified the SIM-klf2-NO pathway at a lower dosage compatible with a high dosage of free SIM, which also led to reduced oxidative stress by decreasing ROS levels. SIM-LipoNPs administration also resulted in a significant reduction in pro-inflammatory cytokines and Collagen I mRNA levels, as a marker of fibrosis. In conclusion, our study highlights the considerable therapeutic potential of using SIM-LipoNPs to prevent liver fibrosis progress, underscoring the remarkable properties of SIM-LipoNPs in activating the KLF2-NO pathway and anti-oxidative and anti-inflammatory response.
The invention discloses a method and a system for generating a cross-modal fusion and memory supervision radiology report, and belongs to the technical field of natural language processing. The invention uses a cross-mode fusion module to promote the information interaction of the visual features of the medical image and the text features of the medical report and solve the problem of insufficient interaction of the multi-mode features. The memory supervision module is used for merging the text information into a normalization layer of the decoder, so that targeted guidance and reference are provided for radiology report generation. And using multi-category contrast loss to enhance the learning of multi-modal features. The invention solves the problems that the current radiology report generates the data deviation of the vision and the text in the cultural relics and the long text is difficult to generate. The precision of the performance of the task is improved, and the method has reference significance for other radiology report generating tasks with similar problems.
Depression is a major public health concern. Emerging research has shown that cognitive behavioral therapy for insomnia (CBT-I) is effective in treating individuals with comorbid insomnia and depression. Traditional face-to-face CBT-I encounters many obstacles related to feasibility, accessibility, and help-seeking stigma. CBT-I delivered via smartphone application could be a potential solution. This two-arm parallel randomized controlled trial (RCT) aims to examine the effectiveness of a smartphone-based self-help CBT-I with a waitlist control group in treating people with major depression and insomnia in Hong Kong.

Participants complete an online rapid screening, followed by a telephone diagnostic interview. Those who meet the eligibility criteria are randomized in a ratio of 1:1 to receive either CBT-I immediately or to a waitlist control condition. The CBT-I consists of six weekly modules and is delivered through a smartphone application known as proACT-S. An online randomized algorithm is used to perform randomization to ensure allocation concealment. The primary outcomes are changes over the measurement points in sleep quality, insomnia severity and depression severity. The secondary outcomes include changes over the measurement points in anxiety, subjective health, treatment expectancy, and acceptability of treatment. Assessments are administered at baseline, post-intervention, and 6-week follow up. The recruitment is underway. Important adverse events, if any, are documented. Multilevel linear mixed model based on intention-to-treat principle will be conducted to examine the effectiveness of the CBT-I intervention

Participants in the CBT-I condition will start CBT-I immediately after randomization; while participants in the waitlist control group will start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment. It is hypothesized that, after the intervention, participants in the CBT-I condition will report a greater decrease in poor sleep quality, depression severity and insomnia severity than those in the waitlist control condition. It is also hypothesized that the reduction in poor sleep quality, depression severity and insomnia severity observed in the CBT-I condition will be maintained at 6-week follow-up. Furthermore, it is hypothesized that participants in the waitlist control condition will report a significant decrease in poor sleep quality, depression severity and insomnia severity after receiving CBT-I.
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Recombinant antibody or antigen-binding fragment thereof is described. This antibody binds IL-13, contains two variable domains, wherein one variable domain comprises the amino acid sequence of SEQ ID NO:80, and the other variable domain comprises the amino acid sequence of SEQ ID NO:81. In addition, said antibody comprises a human heavy chain constant region IgG1 comprising a hinge region comprising replacing leucine with alanine at position 234 (EU numbering) and the replacement of leucine with alanine at position 235 (EU numbering), also contains a constant region of light kappa of the human chain. This antibody blocks the binding of IL-13 to IL-13Rα1 and IL-13Rα2 and is capable of binding to a human IL-13 variant in which the arginine residue at position 130 in SEQ ID NO:1 replaced by the remainder of glutamine. Also described is a nucleic acid encoding a recombinant antibody or its antigen-binding fragment, replication and expression vectors containing such a nucleic acid. Host cells containing these vectors are described. Method for producing antibody or antigen-binding fragment thereof, capable of binding IL-13, including culturing the host cell. Also described is a pharmaceutical composition for treating IL-13 associated disorder that comprises effective amount of a recombinant antibody. Method is provided for treating a subject from a disorder in which the activity of IL-13 is deleterious, comprising the step of administering to the subject antibody or antigen-binding fragment thereof.EFFECT: inventions are useful for detection of hIL-13 and for inhibiting activity of hIL-13, for example in a human suffering from disorder in which hIL-13 activity adversely affects health.32 cl, 23 tbl, 2 ex